Format

Send to

Choose Destination
Nat Med. 2014 Sep;20(9):1043-9. doi: 10.1038/nm.3645. Epub 2014 Aug 17.

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

Author information

1
1] Department of Pathology, Columbia University, New York, New York, USA. [2].
2
1] Department of Dermatology, Columbia University, New York, New York, USA. [2].
3
1] Department of Dermatology, Columbia University, New York, New York, USA. [2] Department of Psychiatry, Columbia University, New York, New York, USA.
4
Department of Dermatology, Columbia University, New York, New York, USA.
5
1] Department of Dermatology, Columbia University, New York, New York, USA. [2] Department of Epidemiology, Columbia University, New York, New York, USA.
6
1] Department of Dermatology, Columbia University, New York, New York, USA. [2] Department of Genetics and Development, Columbia University, New York, New York, USA. [3].
7
1] Department of Pathology, Columbia University, New York, New York, USA. [2] Department of Dermatology, Columbia University, New York, New York, USA. [3] Department of Medicine, Columbia University, New York, New York, USA. [4].

Abstract

Alopecia areata (AA) is a common autoimmune disease resulting from damage of the hair follicle by T cells. The immune pathways required for autoreactive T cell activation in AA are not defined limiting clinical development of rational targeted therapies. Genome-wide association studies (GWAS) implicated ligands for the NKG2D receptor (product of the KLRK1 gene) in disease pathogenesis. Here, we show that cytotoxic CD8(+)NKG2D(+) T cells are both necessary and sufficient for the induction of AA in mouse models of disease. Global transcriptional profiling of mouse and human AA skin revealed gene expression signatures indicative of cytotoxic T cell infiltration, an interferon-γ (IFN-γ) response and upregulation of several γ-chain (γc) cytokines known to promote the activation and survival of IFN-γ-producing CD8(+)NKG2D(+) effector T cells. Therapeutically, antibody-mediated blockade of IFN-γ, interleukin-2 (IL-2) or interleukin-15 receptor β (IL-15Rβ) prevented disease development, reducing the accumulation of CD8(+)NKG2D(+) T cells in the skin and the dermal IFN response in a mouse model of AA. Systemically administered pharmacological inhibitors of Janus kinase (JAK) family protein tyrosine kinases, downstream effectors of the IFN-γ and γc cytokine receptors, eliminated the IFN signature and prevented the development of AA, while topical administration promoted hair regrowth and reversed established disease. Notably, three patients treated with oral ruxolitinib, an inhibitor of JAK1 and JAK2, achieved near-complete hair regrowth within 5 months of treatment, suggesting the potential clinical utility of JAK inhibition in human AA.

PMID:
25129481
PMCID:
PMC4362521
DOI:
10.1038/nm.3645
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center